| Abstract: |
Acute leukemias are characterized by the unrestrained clonal proliferation of hematopoietic precursor cells coupled with aberrant or arrested differentiation. The molecular basis of hematopoiesis and leukemogenesis is still being defined, yet it is increasingly evident that acute leukemias have recurrent molecular features that can be exploited for diagnostic, prognostic, and therapeutic purposes. Modern molecular technologies already influence treatment strategies for these diseases, and it is likely that as such technology matures it will have an increasing impact on all aspects of acute leukemia management. This article reviews recent developments in the molecular classification, prognostication, and treatment of the acute leukemias. Copyright © 2005 by Current Science Inc. |
| Keywords: |
leukemia; acute granulocytic leukemia; gene mutation; mutation; clinical feature; review; drug targeting; methotrexate; molecular genetics; cell proliferation; phenotype; imatinib; diagnostic procedure; low drug dose; liver toxicity; gene expression profiling; protein targeting; gastrointestinal symptom; cytogenetics; cell differentiation; high throughput screening; cell line, tumor; protein tyrosine kinase; biotechnology; cancer therapy; acute lymphoblastic leukemia; gene expression regulation, neoplastic; acute leukemia; reverse transcriptase polymerase chain reaction; rna, messenger; oligonucleotide array sequence analysis; epigenesis, genetic; leukemogenesis; promyelocytic leukemia; medical oncology; chromosome translocation; translocation, genetic; immunophenotyping; hematopoiesis; ras protein; hematopoietic stem cell; pharmacogenetics; bcr abl protein; nucleic acid hybridization; cancer classification; flt3 ligand; comparative genomic hybridization; karyotyping; drug sensitivity; retinoic acid; protein microarray; drug protein binding; hematologic disease; cytochrome p450; gamma secretase inhibitor; notch1 receptor; mercaptopurine; retinoic acid receptor alpha; multidrug resistance protein 1; pharmacogenomics; leukemia, lymphocytic, acute; methylenetetrahydrofolic acid; thiopurine methyltransferase
|
